| 2011 update of the drug resistance mutations in HIV-1 VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, R Shafer, ... Topics in antiviral medicine 19 (4), 156, 2011 | 1250 | 2011 |
| Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans Journal of British Surgery 107 (11), 1440-1449, 2020 | 1145 | 2020 |
| Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update DE Bennett, RJ Camacho, D Otelea, DR Kuritzkes, H Fleury, M Kiuchi, ... PloS one 4 (3), e4724, 2009 | 1113 | 2009 |
| Digital technologies in the public-health response to COVID-19 J Budd, BS Miller, EM Manning, V Lampos, M Zhuang, M Edelstein, ... Nature medicine 26 (8), 1183-1192, 2020 | 1016 | 2020 |
| 2017 update of the drug resistance mutations in HIV-1 AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ... Topics in antiviral medicine 24 (4), 132, 2016 | 757 | 2016 |
| Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel MS Hirsch, HF Günthard, JM Schapiro, FB Vézinet, B Clotet, SM Hammer, ... Clinical Infectious Diseases 47 (2), 266-285, 2008 | 670 | 2008 |
| British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. BG Gazzard HIV medicine 9 (8), 2008 | 524 | 2008 |
| Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study A Banerjee, L Pasea, S Harris, A Gonzalez-Izquierdo, A Torralbo, ... The Lancet 395 (10238), 1715-1725, 2020 | 513 | 2020 |
| Update of the drug resistance mutations in HIV-1: Fall 2006 VA Johnson, F Brun-Vézinet, B Clotet, DR Kuritzkes, D Pillay, ... Top HIV Med 14 (3), 125-130, 2006 | 505* | 2006 |
| Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle-and high-income countries BJA: British Journal of Anaesthesia 117 (5), 601-609, 2016 | 500 | 2016 |
| Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a … L Wittkop, HF Günthard, F De Wolf, D Dunn, A Cozzi-Lepri, A De Luca, ... The Lancet infectious diseases 11 (5), 363-371, 2011 | 471 | 2011 |
| Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global … RK Gupta, MR Jordan, BJ Sultan, A Hill, DHJ Davis, J Gregson, ... The Lancet 380 (9849), 1250-1258, 2012 | 465 | 2012 |
| Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B. 1.1. 7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study D Frampton, T Rampling, A Cross, H Bailey, J Heaney, M Byott, R Scott, ... The Lancet infectious diseases 21 (9), 1246-1256, 2021 | 455 | 2021 |
| HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance RW Shafer, SY Rhee, D Pillay, V Miller, P Sandstrom, JM Schapiro, ... Aids 21 (2), 215-223, 2007 | 429 | 2007 |
| HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression … RK Gupta, J Gregson, N Parkin, H Haile-Selassie, A Tanuri, LA Forero, ... The Lancet infectious diseases 18 (3), 346-355, 2018 | 416 | 2018 |
| Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration R Kantor, DA Katzenstein, B Efron, AP Carvalho, B Wynhoven, P Cane, ... PLoS medicine 2 (4), e112, 2005 | 391 | 2005 |
| Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis J Hemelaar, R Elangovan, J Yun, L Dickson-Tetteh, I Fleminger, S Kirtley, ... The Lancet infectious diseases 19 (2), 143-155, 2019 | 333 | 2019 |
| British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy S Collins, M Fisher, M Johnson, S Khoo, C Leen, C Loveday, G Moyle, ... | 325* | 2003 |
| Update of the drug resistance mutations in HIV-1: March 2013 VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, RW Shafer, ... Topics in antiviral medicine 21 (1), 6, 2013 | 323 | 2013 |
| Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and … RK Gupta, A Hill, AW Sawyer, A Cozzi-Lepri, V von Wyl, S Yerly, VD Lima, ... The Lancet infectious diseases 9 (7), 409-417, 2009 | 316 | 2009 |
